-
Data suggest lower risk of cardiovascular events or deaths in prostate cancer patients treated with degarelix compared to LHRH agonists
in PRESS RELEASE 2013 onData presented today at the European Association of Urology (EAU) 2013 annual meeting in Milan, indicate that the gonadotropin releasing hormone…
-
In patients with active, left-sided ulcerative colitis, study shows once-daily dose of mesalazine granules provided similar results to twice-daily dose
in PRESS RELEASE 2013 onResults of a recent sub analysis1 of data from the MOTUS study2 presented today at the Congress of European Crohn’s and Colitis Organisation…
-
Ferring’s European Marketing Authorisation Application for controlled release misoprostol vaginal delivery system for the induction of labour accepted for review
in PRESS RELEASE 2012 onFerring Pharmaceuticals announced today that it has received confirmation from European health authorities that the Marketing Authorisation…
-
Ferring Announces FDA Acceptance of NDA Filing for Controlled Release Misoprostol Vaginal Insert for Decreasing Time to Vaginal Delivery in Women
in PRESS RELEASE 2012 onFerring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA)…
-
New study showed desmopressin melt reduced sleep disruption in bedwetting children
in PRESS RELEASE 2012 onPreliminary results from a new, prospective study presented today at the first Joint Congress of the International Children’s Continence…
-
Fonds de solidarité FTQ, CTI Life Sciences Fund and Ferring Pharmaceuticals Create a New Biotech in Québec
in PRESS RELEASE 2012 onThe Fonds de solidarité FTQ (the “Fonds”), CTI Life Sciences Fund and Ferring Pharmaceuticals are pleased to announce…
-
FDA approves Ferring’s PREPOPIK™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) for colonoscopy prep
in PRESS RELEASE 2012 onThe U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market PREPOPIK (sodium picosulfate, magnesium…
-
Ferring Pharmaceuticals Acquires Licensing Rights for Elobixibat from Albireo AB
in PRESS RELEASE 2012 onFerring Pharmaceuticals (Ferring) and Albireo AB (Albireo) announced today that they have signed a license agreement under which Ferring has…
-
Ferring Pharmaceuticals donates $10 million to the Salk Institute for Biological Studies
in PRESS RELEASE 2012 onFerring Pharmaceuticals, a global, specialty biopharmaceuticals company, has donated $10 million to support research at the Salk Institute…
-
New data show that FIRMAGON® (degarelix) is non-inferior to the combination of goserelin plus bicalutamide at reducing prostate volume in patients with advanced hormone-dependent prostate cancer while offering better relief from lower urinary tract symptoms
in PRESS RELEASE 2012 onTwo new studies presented at the 27th Annual European Association of Urology (EAU) Congress reported that…
Author archive for pulse
Articles by: pulse
